AstraZeneca inches toward its Cambridge move; Merck teams up with a Danish biotech;

@FierceBiotech: Belgian UCB gets ready for CEO change plus more career changes in biopharma in this week's Chutes & Ladders. | Follow @FierceBiotech

@JohnCFierce: Merck KGaA has the firepower to pull off a big buyout, but will it? Story | Follow @JohnCFierce

@DamianFierce: Ariad's new board member is an activist investor with a history of pushing companies to sell. More | Follow @DamianFierce

@EmilyMFierce: Gene therapy regenerates damaged tissue in pigs after heart attack. Story from FierceBiotech Research | Follow @EmilyMFierce

> Merck ($MRK) has inked a deal with Denmark's Nuevolution to license some small-molecule drugs for undisclosed targets. More

> AstraZeneca ($AZN) has teamed up with Cancer Research U.K. Cambridge Institute, planning to send up to 60 of its scientists to the facility in preparation for its big R&D move. Item

Medical Device News

@FierceMedDev: At J&J's Coridis, at least, renal denervation is continuing to advance. Press release. | Follow @FierceMedDev

@MarkHFierce: I spoke to Daktari Diagnostics' CEO about the company's Series D fundraising efforts. Story via FierceDiagnostics | Follow @MarkHFierce

@MichaelGFierce: BioMérieux's BioFire sets course for GI panel FDA clearance. Article | Follow @MichaelGFierce

@GalenMoore: Sham surgeries: Medtech's placebos? Or a waste of money at patients' risk? via Forbes | Follow @GalenMoore

> Myriad touts positive data for Dx that predicts prostate cancer recurrence. More

> Wall Street cools to CryoLife's new guidance. Story

Pharma News

@FiercePharma: ICYMI: WHO reports success in distributing vaccines at ambient temperatures. Story via FierceVaccines. | Follow @FiercePharma

@EricPFierce: GSK could get some financial breathing room with an EU nod for Anoro. Story | Follow @EricPFierce

@CarlyHFierce: Tops on the old FP site yesterday: Reuters: Bayer, Novartis, Reckitt eye $10B-$12B bids for Merck consumer unit. Story | Follow @CarlyHFierce

> FDA moves toward major overhaul of the way it approves OTC meds. Article

> EU Anoro nod lets GSK breathe deeper as Advair faces generic onslaught. Story

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.